Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 06, 2017 06:05 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Announces ACH-4471 Granted Orphan Drug Designation by the FDA and Positive Opinion for Orphan Drug Designation in the European Union for the Treatment of Paroxysmal Nocturnal Hemoglobinuria

NEW HAVEN, Conn., Nov. 06, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation...
November 01, 2017 16:05 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Reports Third Quarter 2017 Financial Results and Provides Update on Clinical Programs

NEW HAVEN, Conn., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported financial results for the three months ended September 30, 2017. For the third...
October 24, 2017 06:05 ET | Source: Achillion Pharmaceuticals, Inc.

USPTO Grants Composition of Matter Patent to Achillion for ACH-4471, First-in-Class Small Molecule Complement Alternative Pathway Factor D Inhibitor

NEW HAVEN, Conn., Oct. 24, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that the U.S. Patent and Trademark Office (USPTO) has issued a U.S. Patent to...
October 23, 2017 07:00 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Announces Presentation of Data From OMEGA-1 Phase 2b Trial With Odalasvir, AL-335, and Simeprevir (JNJ-4178) at the 2017 Liver Meeting

NEW HAVEN, Conn., Oct. 23, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) reported today Phase 2b data on JNJ-4178, the triple combination consisting of odalasvir, AL-335,...
September 20, 2017 06:05 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion to Present at the 2017 Leerink Partners Rare Disease Roundtable Series

NEW HAVEN, Conn., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that members of the senior management team will provide a corporate update at the...
September 11, 2017 03:02 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Announces Strengthening of Management Team

- Mr. Joseph Truitt promoted to Chief Operating Officer - - Dr. Avner Ingerman joins as Head of Ophthalmology - NEW HAVEN, Conn., Sept. 11, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals,...
September 11, 2017 03:01 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Announces Termination of Worldwide Collaboration for Hepatitis C With Janssen

-Conference call to be held today at 9:00 a.m. ET- NEW HAVEN, Conn., Sept. 11, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that on Saturday, September 9,...
August 08, 2017 16:01 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Reports Second Quarter 2017 Financial Results and Proof-of-Concept With a First-in-Class, Oral Factor D Inhibitor

- Interim results demonstrate ability of ACH-4471 to reduce LDH and improve hemoglobin and fatigue scores in patients with untreated PNH - - Global program expansion planned in PNH, C3G and IC-MPGN -...
August 01, 2017 16:05 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion to Host Second Quarter 2017 Results Conference Call on August 8, 2017

NEW HAVEN, Conn., Aug. 01, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that it plans to report second quarter 2017 financial results on Tuesday, August 8,...
July 10, 2017 16:05 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Pharmaceutials Announces Key Promotion and Discovery Organization Change

NEW HAVEN, Conn., July 10, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), the leader in complement alternative pathway therapeutics, today announced that Mingjun Huang,...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right